TCG Crossover Management, LLC Q1 2022 Filing
Filed May 16, 2022
Portfolio Value
$249.1B
Holdings
20
Report Date
Q1 2022
Filing Type
13F-HR
All Holdings (20 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | OPHTEURIveric Bio, Inc. | 2,516,920 | $42.4B | 17.01% | |
| 2 | VRDNViridian Therapeutics Inc | 1,314,000 | $24.3B | 9.75% | |
| 3 | COGTCogent Biosciences, Inc. | 2,981,042 | $22.3B | 8.96% | |
| 4 | ACRSAclaris Therapeuitics, Inc. | 1,144,939 | $19.7B | 7.92% | |
| 5 | GONGeron Corporation | 14,285,715 | $19.4B | 7.80% | |
| 6 | CBAYUSDCymaBay Therapeutics, Inc. | 5,905,400 | $18.4B | 7.37% | |
| 7 | AVTEAerovate Therapeutics, Inc. | 889,572 | $16.3B | 6.55% | |
| 8 | 290AChinook Therapeutics, Inc. | 882,353 | $14.4B | 5.79% | |
| 9 | TYRATyra Biosciences, Inc. | 896,418 | $9.6B | 3.85% | |
| 10 | TNGXTango Therapeutics, Inc. | 1,254,500 | $9.5B | 3.82% | |
| 11 | NVLSEURAlpine Immune Sciences, Inc. | 1,034,222 | $9.3B | 3.72% | |
| 12 | KURAKura Oncology, Inc. | 506,423 | $8.1B | 3.27% | |
| 13 | MRUSMerus N.V. | 300,000 | $7.9B | 3.18% | |
| 14 | —Akouos, Inc. | 1,350,006 | $6.4B | 2.57% | |
| 15 | —Magenta Therapeutics, Inc. | 2,124,122 | $6.2B | 2.47% | |
| 16 | TRDAEntrada Therapeutics, Inc. | 663,694 | $6.1B | 2.46% | |
| 17 | ZLABZai Lab LTD-ADR | 95,000 | $4.2B | 1.68% | |
| 18 | —Pardes Biosciences, Inc. | 229,100 | $1.7B | 0.66% | |
| 19 | ANABAnaptysBio, Inc. | 58,515 | $1.4B | 0.58% | |
| 20 | —Elevation Oncology, Inc. | 555,000 | $1.4B | 0.56% |